Automating Ancillary Processes: Closing the New Bottleneck in Cell and Gene Therapy Manufacturing

Manual media formulation and viral vector packaging are time-intensive, tedious, and expensive activities. 

In this on-demand webinar, industry experts share challenges encountered when closing and automating ancillary processes, and how improved scalability and reproducibility were achieved by moving to closed automated platforms. 

Access the on-demand recording to hear about:

  • The challenges and benefits of moving media formulation and viral vector packaging from manual to automated systems
  • Reducing process variability and risk
  • Potential future changes that could simply large-scale media formulation and viral vector packaging
  • Economic considerations when evaluating trade-offs of moving to closing formulation and fill systems


David Hodl
Head of Business Development at Invetech

Amy Shaw
Lead, Cell Therapies Engineering and Automation Development at Takeda

Randy Schweickart
Senior Director, Process Technology Development at Bristol Myers Squibb

Farid Ighemat
Sr. Director, Manufacturing, Cell and Gene Therapy - R&D at GlaxoSmithKline

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate vital, emerging therapies from the clinic to commercial-scale manufacturing. Together with our partners, we expand the reach of next-generation medical advances that are revolutionizing healthcare. Learn more at invetechgroup.com 

© Invetech. All rights reserved | Privacy Notice & Cookies Policy